Nuvation Bio Inc. Amortization of Debt Issuance Costs
Nuvation Bio Inc. (NUVB) reported Amortization of Debt Issuance Costs of $671.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfFinancingCosts · last filed 2026-08-06
- Nuvation Bio Inc. amortization of debt issuance costs for the quarter ending 2026-06-30 was $350.00K, a 1844.44% increase year-over-year.
- Nuvation Bio Inc. amortization of debt issuance costs for the quarter ending 2026-03-31 was $321.00K.
- Nuvation Bio Inc. amortization of debt issuance costs for the quarter ending 2025-12-31 was $327.00K.
- Nuvation Bio Inc. amortization of debt issuance costs for the quarter ending 2025-09-30 was $213.00K.
- Nuvation Bio Inc. amortization of debt issuance costs for fiscal 2025 was $662.00K.
- Nuvation Bio Inc. amortization of debt issuance costs for fiscal 2024 was $0.00.
| Period end | Amortization of Debt Issuance Costs | Amortization of Debt Issuance Costs 3 month | Amortization of Debt Issuance Costs 6 month | Amortization of Debt Issuance Costs 9 month | Amortization of Debt Issuance Costs 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $350.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $671.00K 10-Q · filed 2026-08-06 | $998.00K derived: sum of 3 quarters · filed 2026-08-06 | $1.21M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | $321.00K 10-Q · filed 2026-05-04 | $648.00K derived: sum of 2 quarters · filed 2026-05-04 | $861.00K derived: sum of 3 quarters · filed 2026-05-04 | $879.00K derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | $327.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $421.00K 10-K · filed 2026-03-02 | $558.00K derived: sum of 3 quarters · filed 2026-08-06 | $662.00K 10-K · filed 2026-03-02 | |
| 2025-09-30 | $213.00K 10-Q · filed 2025-11-03 | $231.00K derived: sum of 2 quarters · filed 2026-08-06 | $335.00K 10-Q · filed 2025-11-03 | $231.00K derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | $18.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $18.00K 10-Q · filed 2026-08-06 | $18.00K derived: sum of 3 quarters · filed 2026-08-06 | $18.00K derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-25 | $11.00K 10-Q · filed 2025-08-07 | ||||
| 2025-03-31 | $0.00 10-Q · filed 2026-05-04 | $0.00 derived: sum of 2 quarters · filed 2026-05-04 | $0.00 derived: sum of 3 quarters · filed 2026-05-04 | ||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $0.00 derived: sum of 2 quarters · filed 2026-03-02 | $0.00 10-K · filed 2026-03-02 | ||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $0.00 10-Q · filed 2025-11-03 | |||
| 2024-06-30 | $0.00 10-Q · filed 2025-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |